Following advancements in the field of genotoxicology, it has become widely accepted that 3D models are not only more physiologically relevant but also have the capacity to elucidate more complex biological processes that standard 2D monocultures are unable to. Whilst 3D liver models have been developed to evaluate the short-term genotoxicity of chemicals, the aim of this study was to develop a 3D model that could be used with the regulatory accepted in vitro micronucleus (MN) following low-dose, longer-term (5 days) exposure to engineered nanomaterials (ENMs). A comparison study was carried out between advanced models generated from two commonly used liver cell lines, namely HepaRG and HepG2, in spheroid format. While both spheroid systems displayed good liver functionality and viability over 14 days, the HepaRG spheroids lacked the capacity to actively proliferate and, therefore, were considered unsuitable for use with the MN assay. This study further demonstrated the efficacy of the in vitro 3D HepG2 model to be used for short-term (24 h) exposures to genotoxic chemicals, aflatoxin B1 (AFB1) and methyl-methanesulfonate (MMS). The 3D HepG2 liver spheroids were shown to be more sensitive to DNA damage induced by AFB1 and MMS when compared to the HepG2 2D monoculture. This 3D model was further developed to allow for longer-term (5 day) ENM exposure. Four days after seeding, HepG2 spheroids were exposed to Zinc Oxide ENM (0-2 µg/ml) for 5 days and assessed using both the cytokinesis-block MN (CBMN) version of the MN assay and the mononuclear MN assay. Following a 5-day exposure, differences in MN frequency were observed between the CBMN and mononuclear MN assay, demonstrating that DNA damage induced within the first few cell cycles is distributed across the mononucleated cell population. Together, this study demonstrates the necessity to adapt the MN assay accordingly, to allow for the accurate assessment of genotoxicity following longer-term, low-dose ENM exposure.

Department of Nanotoxicology and Molecular Epidemiology Institute of Experimental Medicine of the CAS Prague Czech Republic

In Vitro Toxicology Group Institute of Life Science Swansea University Medical School Singleton Park Campus Swansea Wales UK

Mutagenesis. 2021 Jul 7;36(3):265-268. doi: 10.1093/mutage/geab013. PubMed

See more in PubMed

Pfuhler, S., van Benthem, J., Curren, R., et al. (2020) Use of in vitro 3D tissue models in genotoxicity testing: strategic fit, validation status and way forward. Report of the working group from the 7th International Workshop on Genotoxicity Testing (IWGT). Mutat. Res., 850–851, 503135. PubMed

Mandon, M., Huet, S., Dubreil, E., Fessard, V. and Le Hégarat, L. (2019) Three-dimensional HepaRG spheroids as a liver model to study human genotoxicity in vitro with the single cell gel electrophoresis assay. Sci. Rep., 9, 10548. PubMed PMC

Shah, U.K., Mallia, J.de O., Singh, N., Chapman, K.E., Doak, S.H. and Jenkins, G.J.S. (2018) A three-dimensional in vitro HepG2 cells liver spheroid model for genotoxicity studies. Mutat. Res. Genet. Toxicol. Environ. Mutagen., 834, 35–41. doi:10.1016/j.mrgentox.2018.06.020. PubMed DOI

Štampar, M., Tomc, J., Filipič, M. and Žegura, B. (2019) Development of in vitro 3D cell model from hepatocellular carcinoma (HepG2) cell line and its application for genotoxicity testing. Arch. Toxicol., 93, 3321–3333. PubMed

Llewellyn, S. V., Conway, G.E., Shah, U.K., Evans, S.J., Jenkins, G.J.S., Clift, M.J.D. and Doak, S.H. (2020) Advanced 3D liver models for in vitro genotoxicity testing following long-term nanomaterial exposure. J. Vis. Exp. 2020, 1–10. PubMed

Yamada, K. M. and Cukierman, E. (2007) Modeling tissue morphogenesis and cancer in 3D. Cell, 130, 601–610. PubMed

Lauschke, V.M., Hendriks, D.F.G., Bell, C.C., Andersson, T.B. and Ingelman-Sundberg, M. (2016)Novel 3D culture systems for studies of human liver function and assessments of the hepatotoxicity of drugs and drug candidates. Chem. Res. Toxicol., 29, 1936–1955. PubMed

Schwartz, R. E., Fleming, H. E., Khetani, S. R. and Bhatia, S. N. (2014) Pluripotent stem cell-derived hepatocyte-like cells. Biotechnol. Adv., 32, 504–513. PubMed PMC

Kondo, Y., Iwao, T., Nakamura, K., et al. (2014) An efficient method for differentiation of human induced pluripotent stem cells into hepatocyte-like cells retaining drug metabolizing activity. Drug Metab. Pharmacokinet., 29, 237–243. PubMed PMC

Bell, C. C., Hendriks, D. F., Moro, S. M., et al. (2016) Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease. Sci. Rep., 6, 25187. PubMed PMC

Kermanizadeh, A., Løhr, M., Roursgaard, M., Messner, S., Gunness, P., Kelm, J. M., Møller, P., Stone, V. and Loft, S. (2014) Hepatic toxicology following single and multiple exposure of engineered nanomaterials utilising a novel primary human 3D liver microtissue model. Part. Fibre Toxicol., 11, 56. PubMed PMC

Kammerer, S. and Küpper, J.-H. (2018) Human hepatocyte systems for in vitro toxicology analysis. J. Cell. Biotechnol., 3, 85–93. doi:10.3233/jcb-179012. DOI

Doak, S.H., Manshian, B., Jenkins, G.J.S. and Singh, N. (2012) In vitro genotoxicity testing strategy for nanomaterials and the adaptation of current OECD guidelines. Mutat. Res. Genet. Toxicol. Environ. Mutagen., 745, 104–111. PubMed PMC

Doherty, A., Bryce, S.M. and Bemis, J.C. (2016) The In Vitro Micronucleus Assay. Elsevier Inc., Amsterdam, pp. 161–205.

OECD (2016) Test No. 487: In Vitro Mammalian Cell Micronucleus Test. OECD Publishing, Paris, p. 29.

Curren, R. D., Mun, G. C., Gibson, D. P. and Aardema, M. J. (2006) Development of a method for assessing micronucleus induction in a 3D human skin model (EpiDermTM). Mutat. Res., 607, 192–204. PubMed

Wills, J.W., Hondow, N., Thomas, A.D., et al. (2016) Genetic toxicity assessment of engineered nanoparticles using a 3D in vitro skin model (EpiDermTM). Part. Fibre Toxicol., 13, 50. PubMed PMC

Doak, S. H., Griffiths, S. M., Manshian, B., Singh, N., Williams, P. M., Brown, A. P. and Jenkins, G. J. (2009) Confounding experimental considerations in nanogenotoxicology. Mutagenesis, 24, 285–293. PubMed

Elespuru, R., Pfuhler, S., Aardema, M. J., et al. (2018) Genotoxicity assessment of nanomaterials: recommendations on best practices, assays, and methods. Toxicol. Sci., 164, 391–416. PubMed

Jensen, K.A. and Thieret, N. (2014) The NANOGENOTOX Dispersion Protocol for NANoREG, 13. http://safenano.re.kr/download.do?SEQ=175 (accessed April 15, 2020).

Chapman, K. E., Thomas, A. D., Wills, J. W., Pfuhler, S., Doak, S. H. and Jenkins, G. J. (2014) Automation and validation of micronucleus detection in the 3D EpiDerm™ human reconstructed skin assay and correlation with 2D dose responses. Mutagenesis, 29, 165–175. PubMed PMC

Louis, K. S. and Siegel, A. C. (2011) Cell viability analysis using trypan blue: manual and automated methods. Methods Mol. Biol., 740, 7–12. PubMed

Manshian, B. B., Singh, N. and Doak, S. H. (2013) The in vitro micronucleus assay and kinetochore staining: methodology and criteria for the accurate assessment of genotoxicity and cytotoxicity. Methods Mol. Biol., 1044, 269–289. PubMed

Fenech, M., Chang, W. P., Kirsch-Volders, M., Holland, N., Bonassi, S. and Zeiger, E.; HUman MicronNucleus project . (2003) HUMN project: detailed description of the scoring criteria for the cytokinesis-block micronucleus assay using isolated human lymphocyte cultures. Mutat. Res., 534, 65–75. PubMed

Otieno, M.A., Gan, J. and Proctor, W. (2018) Status and future of 3D cell culture in toxicity testing. In Chen M., Will Y. (eds.), Drug-Induced Liver Toxicity. Methods in Pharmacology and Toxicology. Humana Press Inc., New York, pp. 249–261. Accessed 29 February 2020.

Le Hégarat, L., Mourot, A., Huet, S., Vasseur, L., Camus, S., Chesné, C. and Fessard, V. (2014) Performance of comet and micronucleus assays in metabolic competent HepaRG cells to predict in vivo genotoxicity. Toxicol. Sci., 138, 300–309. PubMed

Jossé, R., Rogue, A., Lorge, E. and Guillouzo, A. (2012) An adaptation of the human HepaRG cells to the in vitro micronucleus assay. Mutagenesis, 27, 295–304. PubMed

Foster, A. J., Chouhan, B., Regan, S. L., et al. (2019) Integrated in vitro models for hepatic safety and metabolism: evaluation of a human Liver-Chip and liver spheroid. Arch. Toxicol., 93, 1021–1037. PubMed

Bell, C. C., Dankers, A. C. A., Lauschke, V. M., et al. (2018) Comparison of hepatic 2D sandwich cultures and 3D spheroids for long-term toxicity applications: a multicenter study. Toxicol. Sci., 162, 655–666. PubMed PMC

Mirab, F., Kang, Y. J. and Majd, S. (2019) Preparation and characterization of size-controlled glioma spheroids using agarose hydrogel microwells. PLoS One, 14, e0211078. PubMed PMC

Friedrich, J., Seidel, C., Ebner, R. and Kunz-Schughart, L. A. (2009) Spheroid-based drug screen: considerations and practical approach. Nat. Protoc., 4, 309–324. PubMed

Wenzel, C., Otto, S., Prechtl, S., Parczyk, K. and Steigemann, P. (2015) A novel 3D high-content assay identifies compounds that prevent fibroblast invasion into tissue surrogates. Exp. Cell Res., 339, 35–43. PubMed

Roy, S., Kulkarni, R., Hewitt, N.J. and Aardema, M.J. (2016) The EpiDermTM 3D human reconstructed skin micronucleus (RSMN) assay: historical control data and proof of principle studies for mechanistic assay adaptations. Mutat. Res. Genet. Toxicol. Environ. Mutagen., 805, 25–37. doi:10.1016/j.mrgentox.2016.05.010. PubMed DOI

Evans, S. J., Clift, M. J., Singh, N., de Oliveira Mallia, J., Burgum, M., Wills, J. W., Wilkinson, T. S., Jenkins, G. J. and Doak, S. H. (2017) Critical review of the current and future challenges associated with advanced in vitro systems towards the study of nanoparticle (secondary) genotoxicity. Mutagenesis, 32, 233–241. PubMed PMC

Corvi, R. and Madia, F. (2017) In vitro genotoxicity testing—can the performance be enhanced? Food Chem. Toxicol., 106, 600–608. PubMed

Council Directive 2010/63/EU (2010) Council Directive 2010/63/EU on the protection of animals used for scientific purposes. Off. J. Eur. Union, 53, 84. doi:10.3000/17252555.L_2010.276.eng. DOI